Status:
UNKNOWN
The Efficacy and Safety of Neoadjuvant Trastuzumab Plus Taxane With and Without Pertuzumab Therapy
Lead Sponsor:
Ahmet Bilici
Collaborating Sponsors:
Medipol University
Bezmialem Vakif University
Conditions:
Breast Cancer
Eligibility:
FEMALE
18+ years
Brief Summary
This study is a Non-Interventional Study (NIS) with secondary data usage. It is designed as a multi-center retrospective cohort study in which the data of adult locally advanced HER2-positive breast c...
Detailed Description
In 2013, the Food and Drug Agency (FDA) granted accelerated approval to pertuzumab for use in the neoadjuvant setting with trastuzumab and chemotherapy for HER2+ locally advanced breast cancer (either...
Eligibility Criteria
Inclusion
- Female patients aged 18 years old and over
- Patients diagnosed as histologically confirmed (IHC score of 3+ and/or positive by ISH) locally advanced HER2-positive breast cancer with breast surgery.
- Patients who received as neoadjuvant therapy.
Exclusion
- Patients transferred from an other hospital should not be included, however, patients' data transferred to an other hospital will be collected till transfer time
Key Trial Info
Start Date :
April 29 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
November 15 2021
Estimated Enrollment :
1500 Patients enrolled
Trial Details
Trial ID
NCT04765124
Start Date
April 29 2021
End Date
November 15 2021
Last Update
June 7 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Medipol University Medical Faculty
Istanbul, Turkey (Türkiye)